Bright Sheland International Co., Ltd. logo

Bright Sheland International Co., Ltd. (4556)

Market Closed
12 Aug, 05:30
TWSE TWSE
NT$
101. 00
+8.9
+9.6634%
NT$
- Market Cap
- P/E Ratio
140% Div Yield
287,005 Volume
- Eps
NT$ 92.1
Previous Close
Add Transaction
Day Range
98.4 101
Year Range
22.3 138
Want to track 4556 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

4556 closed today higher at NT$101, an increase of 9.6634% from yesterday's close, completing a monthly increase of 40.2778% or NT$29. Over the past 12 months, 4556 stock gained 323.4801%.
4556 pays dividends to its shareholders, with the most recent payment made on Aug 05, 2026. The next estimated payment will be in In 11 months on Aug 05, 2027 for a total of NT$0.6.
The last earnings report, released on May 08, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
Bright Sheland International Co., Ltd. has completed 2 stock splits, with the recent split occurring on Aug 28, 2024.
The company's stock is traded on 2 different exchanges and in various currencies, with the primary listing on JPX (JPY).

4556 Chart

Bright Sheland International Co., Ltd. (4556) FAQ

What is the stock price today?

The current price is NT$101.00.

On which exchange is it traded?

Bright Sheland International Co., Ltd. is listed on TWSE.

What is its stock symbol?

The ticker symbol is 4556.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 140%.

What is its market cap?

As of today, no market cap data is available.

Has Bright Sheland International Co., Ltd. ever had a stock split?

Bright Sheland International Co., Ltd. had 2 splits and the recent split was on Aug 28, 2024.

Bright Sheland International Co., Ltd. Profile

Electronic Equipment, Instruments & Components Industry
Information Technology Sector
Mr. Yukihiro Nagatsu CEO
TWSE Exchange
TW0004556006 ISIN
Japan Country
133 Employees
- Last Dividend
- Last Split
- IPO Date

Overview

KAINOS Laboratories, Inc., based in Tokyo, Japan, is a multifaceted company engaged in the development, manufacturing, marketing, distribution, and import/export of a wide array of products. Founded in 1975, originally operating under the name DOMS-IATRON Co., Ltd., it shifted its identity to its current name in the same year. The company’s diverse portfolio encompasses pharmaceuticals, diagnostic reagents, related chemical products, as well as physical and chemical measurement instruments, and medical supplies. Beyond healthcare and scientific markets, KAINOS Laboratories also extends its prowess into the nutrition supplements, foodstuff, animal feed, and related products sectors, establishing itself as a significant entity in both health and science sectors within Japan.

Products and Services

  • Aqua-auto Kainos CRE-IV Test Kit

    A cutting-edge liquid form creatinine measurement reagent kit compatible with a broad range of automatic analyzer systems. This product underscores KAINOS Laboratories’ capability in facilitating advanced biochemical clinical testing.

  • Aqua-auto Kainos ALB Test Kit

    A specialized liquid form reagent kit designed for clinical applications, emphasizing the company’s focus on delivering precise diagnostic tools to the healthcare sector.

  • Aqua-auto Kainos UN-II Test Kit

    This kit stands out for its efficiency in liquid urea nitrogen measurement, showcasing KAINOS Laboratories' commitment to supporting clinical laboratories with high-quality reagents.

  • FGF-23 ELISA Kit

    A two-site enzyme-linked immunosorbent assay kit tailored for the measurement of FGF-23 in serum, reflecting KAINOS Laboratories’ expertise in the niche domain of enzyme analysis.

  • Point of Care Testing Solutions
    • Swiftgene Norovirus GI/GII Kainos

      An innovative diagnostic tool for the detection of noroviruses, enhancing KAINOS Laboratories' influence in the area of infectious disease management through rapid testing.

    • Statmark FLUstick II

      A reliable testing solution for identifying type A and B influenza virus antigens, contributing to the global fight against influenza through fast and efficient diagnostics.

    • Statmark Strep A

      Designed for the detection of Group A beta-hemolytic streptococci, this product signifies KAINOS Laboratories’ dedication to broadening its portfolio in point-of-care diagnostic solutions.

Contact Information

Address: 38-18, Hongo 2-chome
Phone: 81 3 3816 4123